Benjamin Turner

1.4k total citations · 1 hit paper
42 papers, 933 citations indexed

About

Benjamin Turner is a scholar working on Pathology and Forensic Medicine, Rheumatology and Neurology. According to data from OpenAlex, Benjamin Turner has authored 42 papers receiving a total of 933 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pathology and Forensic Medicine, 11 papers in Rheumatology and 9 papers in Neurology. Recurrent topics in Benjamin Turner's work include Multiple Sclerosis Research Studies (24 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Polyomavirus and related diseases (7 papers). Benjamin Turner is often cited by papers focused on Multiple Sclerosis Research Studies (24 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Polyomavirus and related diseases (7 papers). Benjamin Turner collaborates with scholars based in United Kingdom, United States and France. Benjamin Turner's co-authors include Klaus Schmierer, Mónica Marta, Gavin Giovannoni, Sharmilee Gnanapavan, Curtis Offiah, Daniel R. Altmann, David Baker, Jeremy Chataway, Xia Lin and Lance D. Blumhardt and has published in prestigious journals such as Brain, Neurology and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Benjamin Turner

39 papers receiving 916 citations

Hit Papers

Is it time to target no evident disease activity (NEDA) i... 2015 2026 2018 2022 2015 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
    2015 275 citations Gavin Giovannoni, Benjamin Turner et al. Multiple Sclerosis and Related Disorders profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Benjamin Turner United Kingdom 14 687 298 239 195 120 42 933
James Stankiewicz United States 16 584 0.9× 253 0.8× 122 0.5× 143 0.7× 161 1.3× 27 960
Christina Caon United States 20 783 1.1× 381 1.3× 220 0.9× 211 1.1× 122 1.0× 36 1.0k
Claire Hirst United Kingdom 15 900 1.3× 374 1.3× 189 0.8× 267 1.4× 137 1.1× 27 1.2k
Élisabeth Maillart France 17 693 1.0× 439 1.5× 106 0.4× 175 0.9× 146 1.2× 100 1.0k
Leszek Stawiarz Sweden 18 740 1.1× 274 0.9× 118 0.5× 266 1.4× 79 0.7× 35 1.0k
Edgar Carnero Contentti Argentina 17 732 1.1× 465 1.6× 74 0.3× 214 1.1× 105 0.9× 91 957
Robert Glanzman United States 9 529 0.8× 354 1.2× 156 0.7× 128 0.7× 101 0.8× 14 1.1k
C. H. Polman Netherlands 10 788 1.1× 372 1.2× 252 1.1× 265 1.4× 67 0.6× 13 912
Fady Joseph United Kingdom 14 474 0.7× 365 1.2× 128 0.5× 309 1.6× 162 1.4× 23 1.0k
Suzanne Gazda United States 9 621 0.9× 273 0.9× 225 0.9× 166 0.9× 59 0.5× 13 1.0k

Countries citing papers authored by Benjamin Turner

Since Specialization
Citations

This map shows the geographic impact of Benjamin Turner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Turner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Turner more than expected).

Fields of papers citing papers by Benjamin Turner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Turner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Turner. The network helps show where Benjamin Turner may publish in the future.

Co-authorship network of co-authors of Benjamin Turner

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Turner. A scholar is included among the top collaborators of Benjamin Turner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Turner. Benjamin Turner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dubuisson, Nicolas, Mónica Marta, Sharmilee Gnanapavan, et al.. (2023). Anaesthetic management of people with multiple sclerosis. Multiple Sclerosis and Related Disorders. 80. 105045–105045. 2 indexed citations
2.
MacDougall, Amy, Ashok Adams, Lucia Bianchi, et al.. (2023). Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis. Therapeutic Advances in Neurological Disorders. 16. 4223481715–4223481715. 5 indexed citations
3.
Jacobs, Benjamin M., et al.. (2021). Evaluation of remote assessments for multiple sclerosis in an in-home setting. Multiple Sclerosis and Related Disorders. 54. 103125–103125. 3 indexed citations
4.
Reyes, Saúl, Mary Ramsay, Shamez Ladhani, et al.. (2020). Protecting people with multiple sclerosis through vaccination. Practical Neurology. 20(6). 435.1–445. 36 indexed citations
5.
Reyes, Saúl, Sebastián Suárez, Özlem Kayım Yıldız, et al.. (2020). Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis. Multiple Sclerosis and Related Disorders. 41. 102024–102024. 6 indexed citations
6.
Reyes, Saúl, Benjamin Turner, Joela Mathews, et al.. (2019). Severe skin reactions associated with Cladribine treatment in patients with multiple sclerosis (P4.2-022). Neurology. 92(15_supplement).
7.
Turner, Benjamin, Bruce Cree, Ludwig Kappos, et al.. (2019). Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology. 266(5). 1182–1193. 59 indexed citations
8.
Gold, Julian, Mónica Marta, Ute‐Christiane Meier, et al.. (2018). A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study. Multiple Sclerosis and Related Disorders. 24. 123–128. 26 indexed citations
9.
Mao, Zhifeng, César Álvarez-González, Christo Albor, et al.. (2018). Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?. Multiple Sclerosis Journal - Experimental Translational and Clinical. 4(2). 2453203735–2453203735. 7 indexed citations
10.
Keddie, Stephen, Ashok Adams, Andrew Kelso, et al.. (2018). No laughing matter: subacute degeneration of the spinal cord due to nitrous oxide inhalation. Journal of Neurology. 265(5). 1089–1095. 71 indexed citations
11.
Mao, Zhifeng, César Álvarez-González, Özlem Kayım Yıldız, et al.. (2018). Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies. Multiple Sclerosis and Related Disorders. 27. 247–253. 9 indexed citations
12.
Dubuisson, Nicolas, Mark G. Buckley, Mónica Marta, et al.. (2017). Validation of an environmentally-friendly and affordable cardboard 9-hole peg test. Multiple Sclerosis and Related Disorders. 17. 172–176. 10 indexed citations
13.
Meier, Ute‐Christiane, Tove Christensen, Daniel R. Altmann, et al.. (2016). Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results. UCL Discovery (University College London). 1 indexed citations
14.
Marta, Mónica, David MacManus, Tarek Yousry, et al.. (2016). Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study results. Multiple Sclerosis Journal. 21. 2 indexed citations
15.
Pakpoor, Julia, Giulio Disanto, Daniel R. Altmann, et al.. (2015). Cancer Risk is Not Increased in People with Relapsing Multiple Sclerosis Taking Cladribine (P7.011). Neurology. 84(14_supplement). 1 indexed citations
16.
Giovannoni, Gavin, Benjamin Turner, Sharmilee Gnanapavan, et al.. (2015). Is it time to target no evident disease activity (NEDA) in multiple sclerosis?. Multiple Sclerosis and Related Disorders. 4(4). 329–333. 275 indexed citations breakdown →
17.
Smith, Paul, Benjamin Turner, Daniel R. Altmann, et al.. (2015). FLAIR* for the non-invasive histological diagnosis of multiple sclerosis (S29.003). Neurology. 84(14_supplement). 2 indexed citations
18.
Pakpoor, Julia, Giulio Disanto, Daniel R. Altmann, et al.. (2015). No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurology Neuroimmunology & Neuroinflammation. 2(6). e158–e158. 101 indexed citations
19.
Chibbaro, Salvatore, Federico Di Rocco, O. Makiese, et al.. (2011). Neurosurgery and elderly: analysis through the years. Neurosurgical Review. 34(2). 229–234. 43 indexed citations
20.
Pfeffer, Paul, Arjune Sen, Michael Sheaff, et al.. (2010). Eosinophilia, meningitis and pulmonary nodules in a young woman. Thorax. 65(12). 1066–1066. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James Stankiewicz Breakdown of academic impact, for papers by Christina Caon Breakdown of academic impact, for papers by Claire Hirst Breakdown of academic impact, for papers by Élisabeth Maillart Breakdown of academic impact, for papers by Leszek Stawiarz Breakdown of academic impact, for papers by Edgar Carnero Contentti Breakdown of academic impact, for papers by Robert Glanzman Breakdown of academic impact, for papers by C. H. Polman Breakdown of academic impact, for papers by Fady Joseph Breakdown of academic impact, for papers by Suzanne Gazda
Rankless by CCL
2026